- Current value sales of dermatologicals grew by 2% in 2015 to reach ¥142.8 billion in in 2015. Hair loss treatments remained the largest category very closely followed by antipruritics, with retail value sales of ¥37.5 billion and ¥35.6 billion, respectively in 2015. Aging society, woman’s empowerment in the workforce, and rising attention to one’s own appearance amongst young men all worked to drive sales of hair loss treatments. Moreover, when the revised PAL became effective in 2014, internet sales of OTC class one, two and three were approved. For those consumers that had hesitated to purchase hair loss treatments at the counter, the deregulation was helpful, as now they could purchase those products without having in-person communication with store staff. According to Euromonitor International’s beauty and personal care research, top-line hair care grew by 2% in 2014 and manufacturers introduced many added-value products to increase average spend per consumer. The second player in hair care, Unilever, launched a silicone-free shampoo which is believed to be good for scalp health. The rising awareness of scalp healthcare was a following wind to hair loss treatments as well, but at the same time manufacturers of hair loss treatments were required to clarify their positioning as drugs in order to compete against enormous cosmetic products in the hair care category.
- Taisho Pharmaceutical maintained its leading position in dermatologicals with a value share of 19% in 2015, thanks to the dominant hair loss treatment brand RiUP, which accounted for 44% of hair loss treatment value sales. RiUP is the only hair loss treatment classified as a class one OTC, whilst other hair loss treatments such as Daiichi Sankyo Healthcare’s Karoyan Progre and Kao’s Success are classified as class three and quasi-drugs, respectively. Due to its peculiar value as a class one OTC, the RiUP series has higher prices compared to other hair loss treatments, which were relatively strongly impacted by the pullbacks in consumer spending and resulted in a sales decline in 2014 after the VAT increase. In 2015, RiUP saw gentle recovery by 1% from the weak performance in the previous year.
- Dermatologicals is expected to post a value CAGR of 1% at constant 2015 prices over the forecast period to reach sales of ¥152.3 billion in 2020. Hair loss treatments will continue to lead the category due in large part to the increasing senior population who care about their appearance and want to enjoy going out for leisure. Especially senior female consumers are considered to have strong purchasing power and to be willing to pay more for additional value. As this growing consumer segment wishes to enjoy fashion and their leisure time, the demand for hair loss treatment for females is expected to rise accordingly. As is seen in many other OTC categories, manufacturers have chances to appeal to the positive side of hair loss treatment for those who wish to present a younger appearance.
GET MORE FOR LESS!
For orders of 3 or more reports, in addition to your multi-purchase discount, we will provide any strategy or global briefing absolutely free.
Please contact a web site agent using the chat box or complete the form here to receive your free strategic briefing.
Samples (FAQs about samples):Sample Medicated Skin Care Market Research Report
Sample Medicated Skin Care Data
Delivery: Files are delivered directly into your account within a few minutes of purchase.
Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Japan with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Medicated Skin Care industry in Japan, our research will save you time and money while empowering you to make informed, profitable decisions.
The Medicated Skin Care in Japan market research report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volumes and values, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent market research methodology, conducted in-country
Our market research reports answer questions such as:
- What is the market size of Medicated Skin Care in Japan?
- What are the major brands in Japan?
- What are the most popular formats for acne treatments?
Why buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This industry report originates from Passport, our Consumer Health market research database.
Table of Contents
Dermatologicals in Japan - Category Analysis
- Table 1 Sales of Dermatologicals by Category: Value 2010-2015
- Table 2 Sales of Dermatologicals by Category: % Value Growth 2010-2015
- Table 3 NBO Company Shares of Dermatologicals: % Value 2011-2015
- Table 4 LBN Brand Shares of Dermatologicals: % Value 2012-2015
- Table 5 LBN Brand Shares of Hair Loss Treatments: % Value 2012-2015
- Table 6 Forecast Sales of Dermatologicals by Category: Value 2015-2020
- Table 7 Forecast Sales of Dermatologicals by Category: % Value Growth 2015-2020
Dermatologicals in Japan - Company Profiles
Daiichi Sankyo Co Ltd in Consumer Health (Japan)
- Summary 1 Daiichi Sankyo Healthcare Co Ltd: Key Facts
- Summary 2 Daiichi Sankyo Healthcare Co Ltd: Operational Indicators
- Summary 3 Daiichi Sankyo Healthcare Co Ltd: Competitive Position 2015
Taisho Pharmaceutical Co Ltd in Consumer Health (Japan)
- Summary 4 Taisho Pharmaceutical Co Ltd: Key Facts
- Summary 5 Taisho Pharmaceutical Co Ltd: Operational Indicators
- Summary 6 Taisho Pharmaceutical Co Ltd: Competitive Position 2015
Takeda Pharmaceutical Co Ltd in Consumer Health (Japan)
- Summary 7 Takeda Pharmaceutical Co Ltd: Key Facts
- Summary 8 Takeda Pharmaceutical Co Ltd: Operational Indicators
- Summary 9 Takeda Pharmaceutical Co Ltd: Competitive Position 2015
Consumer Health in Japan - Industry Context
Modest positive growth continues
Demographic transition increases necessity of self-medication
Consumer preference of choosing healthcare products diversifies
Self-medication movement may change the role of chemists/pharmacies and drugstores/parapharmacies.
Slow yet positive value performance expected over the forecast period
KEY TRENDS AND DEVELOPMENTS
Japanese government accelerates promotion of self-medication to deal with medical expense caused by aging society.
Premiumised products from major brands lead the market, whilst private label supports price-conscious segment
Remarkable number of inbound tourists enjoys shopping in drugstores/parapharmacies
- Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2010-2015
- Table 9 Life Expectancy at Birth 2010-2015
- Table 10 Consumer Expenditure on Health Goods and Medical Services: Value 2010-2015
- Table 11 Life Expectancy at Birth 2010-2015
- Table 12 Sales of Consumer Health by Category: Value 2010-2015
- Table 13 Sales of Consumer Health by Category: % Value Growth 2010-2015
- Table 14 NBO Company Shares of Consumer Health: % Value 2011-2015
- Table 15 LBN Brand Shares of Consumer Health: % Value 2012-2015
- Table 16 Penetration of Private Label in Consumer Health by Category: % Value 2010-2015
- Table 17 Distribution of Consumer Health by Format: % Value 2010-2015
- Table 18 Distribution of Consumer Health by Format and Category: % Value 2015
- Table 19 Forecast Sales of Consumer Health by Category: Value 2015-2020
- Table 20 Forecast Sales of Consumer Health by Category: % Value Growth 2015-2020
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
- Summary 10 OTC: Switches 2013-2015
- Summary 11 Research Sources